PF-Atlas › Clinical Trials › NCT05644600

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics of Nintedanib in Healthy Participants.

Nintedanib · Phase 1

Registry ID
NCT05644600
Phase
Phase 1
Status
Terminated
Drug / intervention
Nintedanib
Sponsor
AstraZeneca
Start
2023-05-26
Enrollment
18
Locations
1

About this trial

The study is intended to quantify the effect of co-administration and staggered dosing of AZD5055 and nintedanib on exposures of nintedanib in healthy participants.

View NCT05644600 on ClinicalTrials.gov →

Explore related

All Nintedanib trialsAll IPF trials

Related trials

nintedanib — NCT02606877Nintedanib — NCT02598193Nintedanib — NCT02579603Nintedanib — NCT02597933Nintedanib — NCT02999178Nintedanib — NCT02607722
Medical disclaimer. This page summarizes public trial data for NCT05644600 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.